Apyx Medical Corporation — Third Quarter 2026 Earnings Summary

Apyx Medical Corporation reported total revenue of $14.0 million for the third quarter of 2026, representing a 9% increase from the prior year period. The company initiated the full commercial launch of the reusable power liposuction handpiece for its AYON Body Contouring System, which contributed to a 17% growth in the Surgical Aesthetics segment. Net loss attributable to stockholders narrowed to $1.8 million, or $0.04 per share, compared to a $2.0 million loss in the same quarter of 2025, while Adjusted EBITDA turned positive at $0.4 million. Management reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million and updated operating expense expectations to a range of $41.0 million to $42.5 million.